Key result
Rivaroxaban, adjusted via a thrombin generation assay, safely and effectively prevented recurrent skin necrosis and venous thrombosis in a child with severe congenital protein C deficiency.
Why the study?
Does rivaroxaban dose adjustment using a thrombin generation assay prevent the recurrence of skin necrosis or venous thrombosis in a child with severe congenital protein C deficiency?
Does rivaroxaban dose adjustment using a thrombin generation assay prevent the recurrence of skin necrosis or venous thrombosis in a child with severe congenital protein C deficiency?
A thrombin generation assay may be a useful tool to adjust direct oral anticoagulant dosing (like rivaroxaban) in children with thrombophilia to safely prevent thrombosis and skin necrosis.
May support rivaroxaban in select pediatric protein C deficiency cases; leaves optimal dosing and broader use open.
Key Points Rivaroxaban was efficacious and safe in a child with protein C deficiency to prevent the recurrence of skin necrosis or venous thrombosis. The dosage of direct oral anticoagulants in children with thrombophilia is unclear; a thrombin generation assay may be useful to adjust it.
No takes yet. Share an insight, caveat, or question.
Menon et al. (2018) studied this question. Rivaroxaban, adjusted via a thrombin generation assay, safely and effectively prevented recurrent skin necrosis and venous thrombosis in a child with severe congenital protein C deficiency.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: